PMC:7386875 / 1558-2395
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T9 | 129-136 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T26 | 87-95 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T27 | 107-117 | Disease | denotes | thrombosis | http://purl.obolibrary.org/obo/MONDO_0000831 |
| T28 | 366-374 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T29 | 782-790 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T2 | 28-33 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T3 | 129-136 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
| T4 | 143-153 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T5 | 168-173 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T6 | 175-185 | Chemical | denotes | nafamostat | http://purl.obolibrary.org/obo/CHEBI_135466 |
| T7 | 191-203 | Chemical | denotes | dipyridamole | http://purl.obolibrary.org/obo/CHEBI_4653 |
| T8 | 265-274 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T9 | 519-524 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T10 | 5-283 | Sentence | denotes | Several antithrombotic drugs have been proposed as potential therapies to prevent COVID-19-associated thrombosis, including heparin, FXII inhibitors, fibrinolytic drugs, nafamostat, and dipyridamole, many of which also possess pleiotropic anti-inflammatory or antiviral effects. |
| T11 | 284-590 | Sentence | denotes | The growing awareness and mechanistic understanding of the prothrombotic state of COVID-19 patients are driving efforts to more stringent diagnostic screening for thrombotic complications and to the early institution of antithrombotic drugs, for both the prevention and therapy of thrombotic complications. |
| T12 | 591-791 | Sentence | denotes | The shifting paradigm of diagnostic and treatment strategies holds significant promise to reduce the burden of thrombotic complications and ultimately improve the prognosis for patients with COVID-19. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 55 | 375-383 | Species | denotes | patients | Tax:9606 |
| 56 | 768-776 | Species | denotes | patients | Tax:9606 |
| 57 | 129-136 | Chemical | denotes | heparin | MESH:D006493 |
| 58 | 175-185 | Chemical | denotes | nafamostat | MESH:C032855 |
| 59 | 191-203 | Chemical | denotes | dipyridamole | MESH:D004176 |
| 85 | 87-95 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 86 | 107-117 | Disease | denotes | thrombosis | MESH:D013927 |
| 87 | 366-374 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 88 | 447-471 | Disease | denotes | thrombotic complications | MESH:D013927 |
| 89 | 565-589 | Disease | denotes | thrombotic complications | MESH:D013927 |
| 90 | 702-726 | Disease | denotes | thrombotic complications | MESH:D013927 |
| 91 | 782-790 | Disease | denotes | COVID-19 | MESH:C000657245 |